



A new standard in
cholesterol therapy

Forward Looking Statement

This presentation generally summarizes the business information and future plans and potential products of Aqur Biosciences, Inc. (“Aqur” or the “Company”) and is provided for informational purposes only and does not constitute an offer to sell or a solicitation or recommendation to purchase any securities of the Company.

This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based on management’s beliefs and assumptions and on information currently available to management. Most forward-looking statements contain words that identify them as forward-looking, such as “anticipates,” “believes,” “continues,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms that relate to future events. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any projected results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent the beliefs and assumptions of the Company only as of the date of this presentation and the Company undertakes no obligation to update or revise publicly any such forward-looking statements, whether as a result of new information, future events or otherwise. As such, the Company’s future results may vary from any expectations or goals expressed in, or implied by, the forward-looking statements included in this presentation, possibly to a material degree. No forward-looking statement is a guarantee of future results or events, and one should avoid placing reliance on such statements. Aqur undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

The anticipated results contained in this presentation are based on information available at the time of preparation, relying on that information’s accuracy and reliability, and also based on the specific significant assumptions made. Changes in the economic and regulatory factors, among others, as well as additional information or various other events, can change the assumptions as well as the results. This presentation itself does not guarantee its partial or full execution. Therefore, it is possible that this business may not be partially or fully implemented and executed as planned. The Company is not currently adequately capitalized. The Company, upon receiving sufficient capital, intends to conduct independent research and development on its proposed LDL-C lowering compounds utilizing its proprietary next generation LDL-C reducing PCSK9 inhibitors. As of the date of this document, the Company has not independently confirmed nor conducted any research or tests and has not developed or produced any products. If the Company does not receive sufficient capital, it will be unable to research, develop and produce its proposed LDL-C lowering compound utilizing its proprietary next generation LDL-C reducing PCSK9 inhibitors. Aqur cannot be sure when or if it will be permitted by regulatory agencies to undertake clinical trials or to commence any particular phase of any clinical trials. Statements regarding the expected timing or costs of preclinical and clinical trials cannot be regarded as actual predictions of when Aqur will obtain regulatory approval for any phase of clinical trials or the actual costs. We also cannot be sure of the clinical outcome for efficacy or safety of our products.

All dates and times in this presentation are approximations. Material in this document may still contain technical or other inaccuracies, omissions, or errors, for which the Company assumes no responsibility or obligation to update. The Company does not warrant or make any representations regarding the use, validity, accuracy, completeness or reliability of any claims, statements or information in this presentation. This information is not a substitute for independent professional advice before making any investment decisions. The Company has a very limited history of operation, is not adequately capitalized and has no earnings, and this opportunity involves significant risks, which may result in the loss of the total amount of any investment.

All information contained herein contains information that is proprietary, privileged or confidential. It is intended only for the purpose specified and directed to the recipients specifically identified by the Company. Any unauthorized review, disclosure, reproduction, distribution, copying of, or reliance upon this document and any included exhibits is strictly prohibited. The recipient agrees to keep all information garnered from this presentation and from the oral presentation of this presentation strictly confidential.

Agenda

1 ABOUT US
& CORE VALUES s.4-5

2 CHOLESTEROL &
CARDIOVASCULAR DISEASE s.6

3 CURRENT THERAPIES
& MARKET s.7-9

4 THERAPIES UNDER
DEVELOPMENT s.10

5 AQR-008 s.11-13

6 PRELIMINARY RESULTS s.14-16

7 KEY POINTS & PATH
FORWARD s.17-18


8 TEAM s.19-23

9 AT A GLANCE s.24




About Aqur

A pioneering bioscience company
headquartered in Westlake Village,
California, United States



Developing a revolutionary oral
therapy targeting high cholesterol,
addressing a \$25+ billion market

Core Values



Vision

Pioneering a future where cardiovascular disease caused by high cholesterol is effectively treated with cutting-edge, and patient-friendly therapies.

Team

Our team consists of world-renowned scientists, researchers, and industry experts with deep expertise in bioscience, pharmaceutical discovery, and cardiovascular health. Collectively, the team has contributed to the development of over 30 commercial drugs, generating more than \$10 billion in sales.

Mission

Dedicated to advancing breakthrough treatments that address some of the most urgent health challenges, ensuring safety, efficacy, affordability, and accessibility.

High Cholesterol & Cardiovascular Disease



CVD

High cholesterol is a major contributing factor to the Cardiovascular Disease (CVD)

>1 billion

People suffer from high cholesterol globally, affecting approximately ~39% of adults (~94M Americans)

#1

CVD is the number 1 cause of death worldwide, responsible for ~31% of all annual global deaths

18.6 million

Annual cardiovascular deaths, with ~85% attributable to atherosclerotic CVD, primarily caused by elevated LDL

Current Cholesterol Therapeutics: Statins



MoA

Competitive inhibition of enzyme HMG-CoA reductase

LDL

Typical reduction:
30 – 50%

Administration

Oral

Cost

Low

Effect

Reduces cholesterol level & helps stabilize atherosclerotic plaques

Side Effects

Muscle-related & gastrointestinal symptoms, liver enzyme elevation (reversible & rare)

Current Cholesterol Therapeutics: PCSK9i



MoA

mAbs - binds to PCSK9
siRNA - interfere with PCSK9 synthesis

LDL

Typical reduction:
50 – 70%

Administration

Injectable

Cost

High

Effect

Significantly reduces LDL
cholesterol levels in high-risk patients

Side Effects

Injection site reactions, flu-like symptoms,
hypersensitivity or allergic reactions (rare)

Current Market

PCSK9i injectables: ~ \$3.7 Billion



~\$754M Sales in 2024



~\$725M Sales in 2024



~\$1.22B Sales in 2024

Statins (incl. generics): ~ \$16 Billion



~\$1.15B Sales in 2024



~\$2.0B Sales in 2024

2020 - Novartis acquired The Medicines Company for \$9.7B, primarily for inclisiran (Leqvio), then under-development

2020 - AstraZeneca acquired Dogma Therapeutics' oral PCSK9 inhibitor, for an undisclosed amount

Therapies Under Development

Targeting PCSK9

SUPPRESSED PCSK9

AstraZeneca 

AZD0780
CLINICAL RESEARCH PHASE II

 **MERCK**

MK-0616
CLINICAL RESEARCH PHASE III

Targeting LDL-R

PCSK9 UNAFFECTED

 aqur
biosciences

AQR-008
PRE-CLINICAL RESEARCH

Aqur's Oral PCSK9i

Portfolio of over 50 peptides

Patent granted in 2020

Royalty free



AQR-008

Leading candidate

Pre-IND stage

AQR-008: Designed to Explore a New MoA

Targets

EGF-A domain on the
Low-Density Lipoprotein Receptors (LDL-R)

Prevents

PCSK9 binding to LDL-R, process that leads to LDL-R
degradation in the hepatic cell

Allows

LDL-R recycling back to the hepatic cell membrane, and
recurrent binding to LDL particles for clearance




AQR-008: Potential Advantages



- ✓ Oral delivery
- ✓ Minimizes side effects
- ✓ Affordable for patients
- ✓ Improved patient compliance
- ✓ Storage without refrigeration


Preliminary Cholesterol Clearance Results

Aqur's peptides exhibited nearly
3x Cholesterol Clearance




Preliminary Cholesterol Uptake Results

Aqur's leading peptides increase **Cholesterol Uptake** levels (>1.8x) in HepG2 cells



AQR-008: Pre-Clinical Efficacy


Significantly enhanced (>3x)
LDL-R Expression in human hepatic cells
at 50 μ M concentration



AQR-008: Overview of Design, Mechanism, and Potential Effects

STAGE	In pre-clinical studies
MECHANISM OF ACTION	Targets the EFG-A domain on the LDL-R Blocks LDL-R from binding with PCSK9 Prevents LDL-R degradation & enables its recycling
DELIVERY METHOD	Oral
RESULTS & EFFECTS	Significant LDL cholesterol reduction
PCSK9	PCSK9 UNAFFECTED Does NOT bind to PCSK9 Does NOT suppress PCSK9 production Does NOT interfere with other PCSK9 functions
SIDE EFFECTS	Minimal side effects
COMPLIANCE	High compliance due to oral delivery, low cost & minimal side effects
COST	Designed for patient affordability

Path Forward



Management Team



Michael A. Fole, MD, MBA

Chief Executive Officer


- 25+ years of experience in wealth & family office management, banking, trading and investments
- MD - University of Medicine & Pharmacy Carol Davila, Bucharest
- MBA - University of La Verne, California



Jeffrey B. Wolin, JD

President

- 25+ years investment banking, corporate transactions, mergers & acquisitions, public filings and financings
- BS - Biomedical and Chemical Engineering - Columbia University



Andy Jennings, PhD

Chief Scientific Officer

- 35+ years of pharma and biotech industry (GSK, Takeda, & Structure Therapeutics)
- Published in Computational Chemistry, Medicinal Chemistry, Structural Biology, Assay Development, and Bioinformatics
- BSc - Medicinal Chemistry (University of Hertfordshire)
- PhD - Computational Chemistry & Bioinformatics - The Open University, UK



James Hess Leach

Chief Financial Officer

- 40+ years of experience in family office venture capital
- Chairman & Senior Managing Director, National Trust, LLC
- Chair Emeritus, Rhode Island PBS Foundation & Inductee, Rhode Island Heritage Hall of Fame



Michel F. Denarie, MBA

Chief Operating Officer

- 37+ years veteran of the pharmaceutical industry
- 21 years with IQVIA - Senior Principal, Strategic Drug Development - Global COE Lead, Patient Insights - Senior Principal, Commercial Effectiveness
- BS - Kogod School of Business - American University
- MBA - Darden School of Business - University of Virginia

Board of Directors



Michael A. Fole, MD, MBA

Chairman of the Board Designee

- 25+ years of experience in wealth & family office management, banking, trading and investments
- MD - University of Medicine & Pharmacy Carol Davila, Bucharest
- MBA - University of La Verne, California



Jeffrey B. Wolin, JD

Board Designee

- 25+ years investment banking, corporate transactions, mergers & acquisitions, public filings and financings
- BS - Biomedical and Chemical Engineering - Columbia University



Madison F. Richardson, MD

Board Designee


- 40+ years board-certified surgeon
- Officer, Medical Board of California (1987-1993)
- Former Asst. Professor of Surgery, USC & UCLA Medical Schools
- Lt. Col., Walter Reed National Military Medical Center (1968-1979)



Jessica Fieldman

Board Designee

- 10+ years auditor
- BS – Haas School of Business at University of California at Berkeley and Master of Business Taxation - University of Southern California
- Certified Public Accountant California (inactive)
- Formerly auditor at Deloitte
- Transitioned to psychotherapy completing a Master's in Marriage and Family Therapy



David M. Filsoof, MD

Board Designee

- Medical Director of Beverly Hills Cardiovascular
- Fellowship in Cardiovascular Disease at Mayo Clinic
- 10+ years at Cedars Sinai Medical Center
- BA – Emory University
- MD – New York Medical College

Scientific Advisory Board




Roland Wandeler, PhD

- 15+ years of commercial leadership and general management experience in the pharmaceutical & biotechnology industry
- Former Amgen General Manager Germany in Spain & Portugal, and Corporate Vice President & General Manager of Amgen's US Bone Health & Cardiology Business Unit
- MSc & PhD - Chemical Engineering - ETH Zurich



Wayne Paterson

- Director & CEO, Anteris Technologies Ltd
- Former Head of Pharmaceuticals (South Korea) and Head of Commercial Operations (China), Roche Pharmaceuticals
- President, Merck KGaA Europe, Canada and Australia
- Global Head of Cardiovascular Medicine, Merck KGaA (2010-2012)



Jay Horton, MD

- Dr. Horton's characterization of PCSK9 & the protein's interactions with LDL-R provided the foundation for the development of PCSK9i
- Professor of Internal Medicine and Molecular Genetics, Chief of the Division of Digestive & Liver Diseases
- Holds the Robert C. & Veronica Atkin Chair in Obesity & Diabetes Research - University of Texas Southwestern Medical Center at Dallas



Tomi Sawyer, PhD

- Inventor of MCR1 agonist NDP-MSH (Scenesse® by Clinuvel) recently approved by the FDA
- Invented ALRN-6924 (Aileron) and Iclusig® (Ariad/Takeda)
- Former titles: Distinguished Scientist (Merck), CSO (Aileron), SVP (Ariad) & Sr. Director (Pfizer)
- Past President of the American Peptide Society



Nabil Seidah, MC, PhD, OQ, PRSC

- Discovered and cloned seven (PC1, PC2, PC4, PC5, PC7, SKI-1 and PCSK9) of the nine known enzymes belonging to the convertase family
- Author of over 720 peer-review articles & manuscripts
- Recipient of Medical Research Council Scientist Award, McLaughlin Medal of the Royal Society of Canada, the Parizeau Prize of the Association Canadienne-Française, the Pfizer Distinguished Cardiovascular-Metabolic Research Jean-Davignon Award, the Queen Elizabeth II Diamond Jubilee Medal, the "Jacques Genest" Lecturer Award



Michael D. Shapiro, DO

- Professor of Cardiology and Molecular Medicine at Wake Forest University
- Published extensively in the areas of atherosclerosis imaging, lipid disorders, and preventive cardiology with research focuses on PCSK9 physiology and its impact on lipoprotein metabolism
- DO - Rowan University School of Osteopathic Medicine

Scientific Advisory Board



Nicola Ferri, PhD

- Professor in Pharmacology, Department of Medicine, University of Padua, Italy
- Author of >190 peer-review articles & manuscripts, including “Emerging oral therapeutic strategies for inhibiting PCSK9” published in Atherosclerosis Plus
- PhD in “Experimental Pharmacology”
- PhD in “Toxicology of Environment and Nutrition” - University of Milan, Italy



Ajoy Basak, MSc, PhD, FIC

- Inventor of AQR-008
- 25+ years of discovery and development of PCSK9, cholesterol regulation & CVD
- Adjunct Professor, University of Ottawa
- Affiliate Investigator, Ottawa Hospital Research Institute
- Published 150+ peer reviewed articles on PCSK9 enzymes



David M. Lubman, PhD

- Professor Emeritus – University of Michigan Medical School
- Director, The Lubman Lab (University of Michigan Medical School) investigating novel biotechnologies
- MS - Columbia University
- PhD - Stanford University



Bruce Auerbach, MS

- 20+ years of experience in pharmaceutical drug discovery & early clinical development
- Former associate Research Fellow at Pfizer specializing in drug discovery & early clinical development, with a concentration in dyslipidemia and metabolic diseases
- MS in Pathology and Comparative Medicine - Bowman Gray School of Medicine - Wake Forest University



Mary G. Sorci-Thomas, PhD

- Professor of Medicine in the Division of Endocrinology, Metabolism & Clinical Nutrition-Medical School of Wisconsin
- Funded for 33+ years by the National Institutes of Health & for 20 years participated as a Project Leader on an NIH funded Program Project that studied Atherosclerosis and Lipid Metabolism
- PhD - Wake Forest University School of Medicine



Robert E. Burrier, PhD

- Career technology executive with experience in pharmaceutical research
- Participated & led programs resulting in drugs currently on the market including Zetia & Vytorin
- RGD at Schering-Plough, Merck KGaA, Eli Lilly, GelTex, and Genzyme
- PhD - Boston University, Postdoctoral Fellowship in Comparative Medicine - Wake Forest University

Scientific Advisory Board



Amanuel Sima, MD

- 24+ years board-certified physician
- Board-certified physician specializing in internal medicine
- Diplomate of the American Board of Internal Medicine, the American Board of Pulmonary Medicine, & the American Board of Critical Care Medicine



Khaled Machaca, PhD

- Senior Associate Dean for Research, Innovation and Commercialization, Weill Cornell Medicine-Qatar & Professor of Physiology and Biophysics, Weill Cornell Medicine
- Machaca Lab investigates Ca^{2+} signaling, non-genomic progesterone signaling, and personalized treatments for monogenic disorders, with continuous support from NIH and QRDI
- Serves on editorial boards, reviews for journals and funding bodies, and has a strong record of student and postdoc mentorship

At a Glance



aqur
biosciences

Innovation

Unique Mechanism of Action

Strategy

Proven Development Pathway

Target

Large Addressable Market

Advantage

Oral, Affordable, Accessible



Thank You!

We look forward to the journey ahead,
where we can turn our vision into reality.



www.aqurbiosciences.com



+1 (818) 698-1006



info@aqurbiosciences.com



2829 Townsgate Road, Suite 100, Westlake Village, CA 91361